By: IPP Bureau
Last updated : February 15, 2026 11:14 am
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
NATCO Pharma Limited received approval for Semaglutide from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March’26.
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.